Roche ends research deal with Ligand

Roche (SIX:ROG; OTCQX:RHHBY) plans to terminate a 2008 deal with Ligand Pharmaceuticals Inc. (NASDAQ:LGNDD) to develop nucleosides using HepDirect liver-targeting technology. Ligand gained the technol...